User:Mr. Ibrahem/Bivalirudin

Mr. Ibrahem/Bivalirudin
Clinical data
Trade names	Angiomax, Angiox, others
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN;
Routes of; administration	Intravenous
Drug class	Direct thrombin inhibitor (DTI)
Legal status
Legal status	US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	N/A (IV application only)
Metabolism	cleared from plasma by a combination of kidneys and proteolytic cleavage
Elimination half-life	~25 minutes with normal kidney function
Chemical and physical data
Formula	C98H138N24O33
Molar mass	2180.317 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]5CCCN5C(=O)[C@@H](CC6=CC=CC=C6)N;
	InChI InChI=1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1 ; Key:OIRCOABEOLEUMC-GEJPAHFPSA-N ;
	(what is this?) (verify)

Bivalirudin, sold under the brand names Angiomax and Angiox, is a medication used during percutaneous coronary intervention (PCI).^[1] It can be used in people with heparin-induced thrombocytopenia (HIT).^[1] It is given by injection into a vein.^[1]

Common side effects include bleeding.^[1] Safety in pregnancy is unclear.^[1] It is a direct thrombin inhibitor (DTI) and a manufactured version of hirudin.^[1]^[2]

Bivalirudin was approved for medical use in the United States in 2000.^[1] While it was approved in Europe in 2004, this approval was subsequently withdrawn.^[3] It is available as a generic medication.^[2] In the United States 250 mg costs about 115 USD as of 2022.^[4]

References edit

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "DailyMed - BIVALIRUDIN injection". dailymed.nlm.nih.gov. Archived from the original on 11 April 2021. Retrieved 10 January 2022.
^ ^a ^b "Bivalirudin Monograph for Professionals". Drugs.com. Archived from the original on 5 March 2021. Retrieved 11 January 2022.
^ "Angiox". Archived from the original on 24 March 2021. Retrieved 10 January 2022.
^ "Bivalirudin Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 11 January 2022.

[PI2022-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "DailyMed - BIVALIRUDIN injection". dailymed.nlm.nih.gov. Archived from the original on 11 April 2021. Retrieved 10 January 2022.

[AHFS2022-2] "Bivalirudin Monograph for Professionals". Drugs.com. Archived from the original on 5 March 2021. Retrieved 11 January 2022.

[EPAR2022-3] "Angiox". Archived from the original on 24 March 2021. Retrieved 10 January 2022.

[4] "Bivalirudin Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 11 January 2022.

[1]

[2]

[3]

[4]